These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 22328538)
1. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Beukelman T; Haynes K; Curtis JR; Xie F; Chen L; Bemrich-Stolz CJ; Delzell E; Saag KG; Solomon DH; Lewis JD; Arthritis Rheum; 2012 Apr; 64(4):1263-71. PubMed ID: 22328538 [TBL] [Abstract][Full Text] [Related]
2. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Beukelman T; Xie F; Chen L; Baddley JW; Delzell E; Grijalva CG; Lewis JD; Ouellet-Hellstrom R; Patkar NM; Saag KG; Winthrop KL; Curtis JR; Arthritis Rheum; 2012 Aug; 64(8):2773-80. PubMed ID: 22569881 [TBL] [Abstract][Full Text] [Related]
3. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis. Kok VC; Horng JT; Huang JL; Yeh KW; Gau JJ; Chang CW; Zhuang LZ BMC Cancer; 2014 Aug; 14():634. PubMed ID: 25174953 [TBL] [Abstract][Full Text] [Related]
4. Risk of Tuberculosis in Children with Juvenile Idiopathic Arthritis: A Nationwide Population-Based Study in Taiwan. Hsin YC; Zhuang LZ; Yeh KW; Chang CW; Horng JT; Huang JL PLoS One; 2015; 10(6):e0128768. PubMed ID: 26047099 [TBL] [Abstract][Full Text] [Related]
6. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155 [TBL] [Abstract][Full Text] [Related]
7. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis]. Horneff G Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787 [TBL] [Abstract][Full Text] [Related]
8. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Horneff G; Klein A; Oommen PT; Hospach A; Foeldvari I; Feddersen I; Minden K Clin Exp Rheumatol; 2016; 34(6):1113-1120. PubMed ID: 27749226 [TBL] [Abstract][Full Text] [Related]
9. Juvenile idiopathic arthritis and malignancy. Ruperto N; Martini A Rheumatology (Oxford); 2014 Jun; 53(6):968-74. PubMed ID: 24185766 [TBL] [Abstract][Full Text] [Related]
10. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001 [TBL] [Abstract][Full Text] [Related]
11. A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors. Walters HM; Pan N; Lehman TJ; Adams A; Huang WT; Sitaras L; Cunningham-Rundles S; Walsh TJ; Toussi SS Clin Rheumatol; 2015 Mar; 34(3):457-64. PubMed ID: 25227771 [TBL] [Abstract][Full Text] [Related]
12. Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. Shafferman A; Fontaine KR; Cron RQ; Beukelman T J Rheumatol; 2014 Jan; 41(1):113-8. PubMed ID: 24293573 [TBL] [Abstract][Full Text] [Related]
13. Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Bichler J; Benseler SM; Krumrey-Langkammerer M; Haas JP; Hügle B Scand J Rheumatol; 2015; 44(4):280-3. PubMed ID: 25993023 [TBL] [Abstract][Full Text] [Related]
14. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. Nordstrom BL; Mines D; Gu Y; Mercaldi C; Aquino P; Harrison MJ Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1357-64. PubMed ID: 22511558 [TBL] [Abstract][Full Text] [Related]
15. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis. Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of and factors associated to chronic kidney disease and hypertension in a cohort of children with juvenile idiopathic arthritis. Gicchino MF; Di Sessa A; Guarino S; Miraglia Del Giudice E; Olivieri AN; Marzuillo P Eur J Pediatr; 2021 Feb; 180(2):655-661. PubMed ID: 32860100 [TBL] [Abstract][Full Text] [Related]
17. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434 [TBL] [Abstract][Full Text] [Related]
18. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Foeldvari I; Becker I; Horneff G Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824 [TBL] [Abstract][Full Text] [Related]
19. Incidence of herpes zoster infections in juvenile idiopathic arthritis patients. Nimmrich S; Horneff G Rheumatol Int; 2015 Mar; 35(3):465-70. PubMed ID: 25583050 [TBL] [Abstract][Full Text] [Related]
20. Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors. Mannion ML; Xie F; Curtis JR; Beukelman T J Rheumatol; 2014 Oct; 41(10):2078-84. PubMed ID: 25086081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]